| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5472949 | CHEPLAPHARM | N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same |
Dec, 2013
(10 years ago) | |
|
US5472949 (Pediatric) | CHEPLAPHARM | N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same |
Jun, 2014
(9 years ago) | |
Xeloda is owned by Cheplapharm.
Xeloda contains Capecitabine.
Xeloda has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Xeloda are:
- US5472949
- US5472949*PED
Xeloda was authorised for market use on 30 April, 1998.
Xeloda is available in tablet;oral dosage forms.
Xeloda can be used as method of treating tumors.
The generics of Xeloda are possible to be released after 10 June, 2017.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-131) | Dec 10, 2016 |
| Pediatric Exclusivity(PED) | Jun 10, 2017 |
Drugs and Companies using CAPECITABINE ingredient
Market Authorisation Date: 30 April, 1998
Treatment: Method of treating tumors
Dosage: TABLET;ORAL
How can I launch a generic of XELODA before it's drug patent expiration?
More Information on Dosage
XELODA family patents
